Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Category	Detail
Condition	Obesity and obesity with type 2 diabetes
Key Mechanisms	Once-weekly injectable semaglutide 7.2 mg reduces excess body weight and maintains long-term weight reduction
Target Population	Adults with obesity, including those with type 2 diabetes; also approved for pediatric patients aged 12 years and older
Care Setting	Outpatient management with lifestyle intervention

FDA approved semaglutide 7.2 mg (Wegovy HD) based on phase 3 STEP UP trials demonstrating significant weight loss
Mean weight loss of 20.7% in adults with obesity and 14.1% in adults with obesity and type 2 diabetes over 72 weeks
Safety and tolerability consistent with previous semaglutide studies; multiple formulations approved including injectable and oral

Identify adults with obesity or overweight, including those with type 2 diabetes, as candidates for semaglutide therapy

Administer semaglutide 7.2 mg once weekly via injection alongside lifestyle interventions
Consider semaglutide for long-term weight reduction and maintenance
Use in adults and pediatric patients aged 12 years and older as indicated

Potential adverse effects consistent with prior semaglutide studies; monitor accordingly

Approximately 1,400 adults with obesity and 500 adults with obesity and type 2 diabetes in clinical trials

Significant mean weight loss achieved (20.7% and 14.1%, respectively) with a favorable safety and tolerability profile

Incorporate semaglutide 7.2 mg as part of a comprehensive obesity management plan including lifestyle modification
Educate patients on the importance of adherence to once-weekly dosing
Monitor for efficacy and adverse effects regularly
Consider semaglutide for patients with obesity-related comorbidities such as type 2 diabetes and cardiovascular disease